Barclays PLC Boosts Stock Position in AxoGen, Inc. (NASDAQ:AXGN)

Barclays PLC raised its stake in AxoGen, Inc. (NASDAQ:AXGN) by 119.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 72,036 shares of the medical equipment provider’s stock after acquiring an additional 39,182 shares during the period. Barclays PLC’s holdings in AxoGen were worth $1,010,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Quest Partners LLC grew its position in AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 2,076 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of AxoGen in the 3rd quarter worth $56,000. Acadian Asset Management LLC purchased a new stake in shares of AxoGen in the second quarter valued at about $125,000. Oppenheimer & Co. Inc. acquired a new position in shares of AxoGen during the third quarter worth about $156,000. Finally, Quantbot Technologies LP purchased a new position in AxoGen during the third quarter worth about $165,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $15.00.

AxoGen Price Performance

Shares of NASDAQ AXGN opened at $18.24 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. AxoGen, Inc. has a one year low of $5.55 and a one year high of $18.49. The firm has a market capitalization of $802.71 million, a P/E ratio of -57.00 and a beta of 1.01. The company’s fifty day moving average is $14.73 and its two-hundred day moving average is $12.80.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.